Role of Tissue Factor Pathway Inhibitor-2 in Ovarian Tumor Migration and Invasion

Abstract

Objective: To elucidate the relation between human tissue factor pathway inhibitor-2 (TFPI- 2) expression and ovarian tumor migration and invasion. Methods: Human TFPI-2 expression vector pBos-Cite-neo/TFPI-2 was transfected into ovarian tumor cells line A2780. After the transfected cells were selected by G418, transfected and nontransfected cells were screened for TFPI-2 mRNA and protein by reverse transcription-polymerase chain reaction and Western blot analysis, respectively. The number of transfected or nontransfected cells passing through membrane of Boyden chamber was counted as the basis assessing tumor cells migratory and invasive behaviors. Results: Expression of mRNA and protein of TFPI-2 was detectable in transfected cells. In invasion assay, the number of TFPI-2-expressing cells to traverse a Matrigel-coated membrane was obviously decreased compared with that of nonexpressing cells (59.3±6.5 vs 109.7±5.5, P<0.01); While in migration assay, no significant difference through a noncoated membrane was observed among transfected and nontransfected cells (114.7±8.6 vs 127.3±7.1, P>0.05). Conclusion: Expression of TFPI-2 may strongly inhibit the invasive ability of ovarian tumor cells in vitro, but has no effect on the migratory ability which provides an experimental basis for genotherapy of human ovarian tumor.